| DC80018 |
VV116
|
VV116, also known as JT001, is an oral drug candidate of nucleoside analog against SARS-CoV-2. VV116 is a deuterated, tri-isobutyrate ester prodrug of the RDV parent nucleoside, and is rapidly metabolized into the parent nucleoside (116-N1) in the body. 116-N1 is intracellularly converted to the nucleoside triphosphate active form, which would interfere with the function of RNA-dependent RNA polymerase of SARS-CoV-2, thus exerting antiviral effects (Fig. 1). VV116 showed potent activity against a panel of SARS-CoV-2 variants (alpha, beta, delta, and omicron) and excellent therapeutic efficacy in the mice model. |
| DC59016 |
Ensitrelvir (S-217622)
|
S-217622 is the first oral non-covalent, non-peptidic SARS-CoV-2 3CL protease inhibitor with IC50 of 0.096 μM. S-217622 displays antiviral activity in vitro towards a range of SARS-CoV-2 variants and coronavirus families, favorable drug metabolism and pha |
| DC58060 |
VV116 (non-deuterated)
|
non-deuterated form of VV116.VV116 is an oral drug candidate of nucleoside analog against SARS-CoV-2. |
| DC58000 |
4'-fluorouridine (4'-FlU, EIDD-2749)
|
4'-fluorouridine (4'-FlU, EIDD-2749) is a ribonucleoside analog that inhibits respiratory syncytial virus (RSV), related RNA viruses, and SARS-CoV-2 with high selectivity index (EC50/CC50 of ≥1877) in cells and human airway epithelia organoids. 4'-FlU induces a delayed stalling of RSV and SARS-CoV-2 RdRP (RNA-dependent RNA polymerase). |
| DC57120 |
PF07321332(nirmatrelvir)
|
PF07321332(nirmatrelvir) is a potent and orally active SARS-CoV 3C-like protease (3CLPRO) inhibitor . PF-07321332 targets to the SARS-CoV-2 virus and can be used for COVID-19 reseacrch. |
| DC53050 |
ATI-2173
|
ATI-2173 is a novel liver-targeted molecule designed to deliver the 5′-monophosphate of clevudine for the treatment of chronic hepatitis B infection. |
| DC39115 |
LCB-1 protein
|
LCB-1 is a designed antiviral protein inhibiting SARS-CoV-2. LCB1 is roughly six times more potent on a per mass basis than the most effective monoclonal antibodies reported thus far.LCB1 is currently being evaluated in rodents. LCB1 binds the Spike receptor binding domain (RBD) with affinity below 1 nM and blocks ARS-CoV-2 infection of Vero E6 cells with IC50 of 23.54 pM. |
| DC39053 |
XP-59
|
XP-59 is a potent inhibitor of the SARS-CoV Mpro, with a Ki of 0.1 μM[1].The SARS-CoV main proteinase (Mpro) plays a central role in the formation of the viral replicase/transcriptase complex and is thus an ideal target for the development of suitable dru |
| DC39042 |
FGI-106
|
FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 tetrahydrochloride also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC50s of 200 nM and 150 nM, respectively[1].FGI-106 is a potent compound for COVID-19 treament. |
| DC39024 |
AT-527(Bemnifosbuvir hemisulfate)
|
AT-527(Bemnifosbuvir hemisulfate), a hemisulfate salt of AT-511, a guanosine nucleotide prodrug, is a potent and orally active HCV viral replication inhibitor. AT-527 is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM). Bemnifosbuvir hemisulfate has pangenotypic antiviral activity[1][2][3].Bemnifosbuvir hemisulfate has pan-genotypic antiviral activities that inhibits HCV genotype 1a (HCV GT1a), HCV GT1b, HCV GT2a, HCV GT3a, HCV GT4a, and HCV GT5a replication with EC50 values of 12.8 nM, 12.5 nM, 9.2 nM, 10.3 nM, 14.7 nM, and 28.5 nM, respectively[1].
In normal human airway epithelial cells, the concentration of Bemnifosbuvir hemisulfate required to inhibit replication of SARS-CoV-2 by EC90 is 0.47 μM, very similar to its EC90 against HCoV-229E, HCoV-OC43 and SARS-CoV in Huh-7 cells[2].When given orally to rats (500 mg/kg) and monkeys (30 mg/kg, 100 mg/kg or 300 mg/kg), Bemnifosbuvir hemisulfate preferentially delivers high levels of AT-9010 in the liver in vivo[1]. |
